The agency must still complete its review and decide whether and how to act
Your muscle cells are essentially becoming better hydrated, which can improve performance and recovery
Constipation management Tirzepatide slows the entire gastrointestinal tract, not just the stomach
Coverage Considerations Saxenda: Longer FDA approval history (2014) may mean better coverage on some plans Step therapy: Some plans require trying Saxenda before approving Zepbound Zepbound: Superior efficacy (20.9% vs ~8% weight loss) may justify coverage even if more expensive Cash Pay Options If insurance doesn't cover your preferred option: Zepbound via LillyDirect: $299$449/month (vials, Dec 2025) Saxenda: ~$1,400/month retail
The lowest effective dose in males (0.01 mg/kg) failed to significantly reduce alcohol-appropriate responding in females, suggesting lower sensitivity in females
Regulatory momentum continues: FDA submission for weight management (based on REDEFINE 1 and 2) occurred in December 2025 , with a decision expected late 2026